美国麻省理工学院、哈佛大学及麻省总医院的科研团队开发出一款 人工智能（AI）软件，能够利用 算 法自动解析脑干中以往难以清晰成像的白质神经束。这一成果打开了研究脑干的新窗口，也为研究神经 系统疾病与脑损伤提供了新工具。该研究发表于《美国国家科学院院刊》。 ...

转自：新华财经 新华财经上海2月19日电 （谷青竹）19日，上海交通大学医学院附属新华医院（以下简称"新华医院"） 传来重大科研消息：该院两项原创性研究成果登上国际顶级学术期刊《自然》（Nature），分别在罕见 病AI诊断、神经发育疾病基因治疗领域实现重大突破。 研究团队首先构建了复刻患者核心症状的人源化突变小鼠模型，为治疗研究搭建精准的"疾病模拟平 台"；并创新性设计出新型腺嘌呤碱基编辑器TeABE，与传统技术相比，全程无DNA双链断裂风险，大 幅降低基因组紊乱风险。实验显示，编辑器成功抵达突变小鼠多个脑区实现靶向修复，其社交回避、认 知迟钝、运动不协调等行为异常得到显著改善。更重要的是，团队在非人灵长类（猕猴）模型中开展实 验，也成功检测到明确的碱基编辑活性，验证了该技术的跨物种应用可行性，为后续临床试验积累了充 足前期数据。 据悉，新华医院团队深耕儿童神经发育障碍领域二十余年，致力于其遗传及环境病因的基础到临床转化 研究。李斐团队聚焦基因精准编辑，在《自然》发表重磅成果的同时，还在环境病因研究方面有所突 破，近期牵头完成的"神经发育障碍的生命早期环境风险因素识别和防控体系建立与推广"项目，在2025 ...

在推理过程上，它实现全流程白盒推理，每一个诊断结论都附带完整证据链条，让医生既能知道诊断结 果，更清楚诊断依据，彻底破解AI医疗的"信任难题"。 孙锟教授告诉记者，罕见病诊疗长期面临"不测基因就难确诊"的行业困境，尤其在缺乏基因检测条件的 基层医院，罕见病筛查更是难上加难。DeepRare实现了罕见病表型筛查性能的跨越式提升。研究显示， 在仅提供患者临床表型信息、无基因数据的情况下，DeepRare展现出超强的"表型解码"能力，表型诊断 首位准确率达57.18%，较此前国际最佳模型提升23.79个百分点。这为基层医院打造了一把罕见病快速 筛查的"金钥匙"，让基层无需依赖复杂基因检测，也能开展高效的罕见病初筛。当引入基因测序数据 后，DeepRare的诊断效能进一步升级，在复杂病例中的综合首位诊断准确率突破70.6%，明显优于国际 通用的Exomiser工具(53.2%)。 据了解，DeepRare的应用落地已先行一步，DeepRare罕见病在线诊断平台已于2025年7月26日正式上 线，凭借精准的诊断能力和便捷的使用体验，迅速获得全球医疗科研领域的认可。平台上线短短半年， 已吸引超1000名专业用户注册，覆盖 ...

据中国糖尿病杂志消息，我国著名内分泌学和糖尿病学专家、糖尿病防治专业主要奠基人与发展推动 者、中国糖尿病杂志名誉主编及创办人、北京大学糖尿病中心名誉主任、北京大学第一医院主任医师钱 荣立教授，因病医治无效，于2026年2月7日在北京辞世，享年93岁。 作为我国首部《中国糖尿病防治指南》制定的组织者和主要撰稿人，钱荣立带领我国糖尿病和相关学科 专家将国际前沿知识与我国临床实践相结合，以严谨求实的科学态度，为指导我国糖尿病诊断、治疗、 预防和管理制定了纲领性的文件。他撰写出版了《糖尿病及其并发症的当代治疗》《21世纪的糖尿病防 治》《糖尿病临床指南》及Current Status of Diabetes in East Asia等专著。 智通财经记者 蒋子文 作为中华医学会糖尿病学分会主要创始人与领导者之一，钱荣立为我国糖尿病专业队伍的壮大、学术交 流平台的构建以及国际影响力的提升奠定了坚实基础。他以其深邃的学术洞察力和卓越的组织才能，引 领了中国糖尿病学的发展方向。他于1991年至2003年先后任中华医学会糖尿病学分会副主任委员和主任 委员，1996年被聘任为卫生部糖尿病防治专家咨询委员会副主任委员。 1993 ...

以往，超声神经调控技术主要被用在功能性脑部疾病的治疗中。此次，研究团队探索将其用在脑部恶性 程度最高的胶质母细胞瘤的治疗中。胶质母细胞瘤的恶性程度非常高，在脑部恶性肿瘤中占比约三成。 总体而言，患者生存时间在16个月左右。据悉，以往胶质母细胞瘤的治疗用的是化学方法，效果都不理 想，因为血脑屏障阻碍了药物进入大脑。 研究团队尝试采用物理方法——以超声作为技术媒介，打开血脑屏障进而提高药物入脑的浓度。史之峰 教授解释，超声波本身十分安全，因此可以用在孕产妇的产前检查。在此次研发中，研究团队克服了诸 多技术难点，以确保在最大安全程度下为患者实施最有效的脑肿瘤治疗。 血脑屏障是大脑的保护层，阻止有害物质和细菌进入大脑，在保护人类中枢神经系统的同时，也阻碍了 不少脑部疾病的有效治疗。如何安全打开血脑屏障实现更为有效的治疗，而后顺利闭合血脑屏障，是医 学界致力攻克的难题。 近日，在国家重点研发计划项目：《面向脑肿瘤诊疗一体化的超声脑机植入系统技术研究及样机研制》 启动会上，复旦大学联合华山医院神经外科共同发布了最新研究成果：利用中国自主研制的超声诊疗一 体化装置（UltraBrainPad），专家采用超声神经调控技术，成 ...

Core Viewpoint - Chongqing Medical University has announced procurement intentions for 17 items of laboratory equipment, with a total budget of 89.37 million yuan, scheduled for purchase between September 2025 and December 2026 [1][2]. Procurement Summary - The procurement includes various advanced laboratory instruments such as: - Flow cytometry analyzer, budgeted at 200,000 yuan, aimed at detailed immunological cell typing and monitoring [4]. - Fully automated protein immunoblotting system, budgeted at 250,000 yuan, for protein separation and detection [5]. - Digital PCR system, budgeted at 80,000 yuan, for biomarker research and gene expression analysis [6]. - Cell immune analysis instrument, budgeted at 318,000 yuan, for immunological research [6]. - Mass spectrometer, budgeted at 280,000 yuan, for rapid qualitative and quantitative analysis in various fields [7]. - Gene sequencer, budgeted at 220,000 yuan, for high-throughput sequencing applications [7]. - Other equipment includes a tunnel-type cage washer, high-speed refrigerated centrifuge, and various analytical instruments, with budgets ranging from 64,000 to 3.5 million yuan [8][9][11]. Equipment Requirements - All equipment must meet national standards and technical specifications, ensuring reliability and safety [4][5][6]. - Suppliers must provide comprehensive technical support, including training and maintenance services, with a minimum operational uptime of 99% [5][6][9]. - The procurement process emphasizes the need for after-sales service, including regular maintenance and timely response to service requests [9][11].

Group 1: Foreign Trade Performance - In 2025, Tianjin's total foreign trade import and export value reached 835.87 billion yuan, with exports exceeding 400 billion yuan for the first time, marking a year-on-year increase of 10.1% [1] - The export value of private enterprises in Tianjin reached 843.6 billion yuan, a year-on-year growth of 4.1%, with the number of exporting enterprises reaching a historical high of 11,400 [1] - The export of mechanical and electrical products was the largest category, totaling 871 billion yuan, accounting for over 60% of the city's total exports, with a year-on-year increase of 10.3% [1] Group 2: Cross-Border RMB Transactions - In 2025, Tianjin's cross-border RMB payment volume exceeded 630 billion yuan, a year-on-year increase of 17%, marking a historical high and achieving 3.5 times the scale of 2019 [11] - The volume of cross-border RMB business in Tianjin's goods trade grew by 24% year-on-year, accounting for over 30% of total foreign and domestic currency settlements [11] - The issuance of "Panda bonds" by overseas enterprises reached 6.8 billion yuan, with a year-on-year growth of 130% [11] Group 3: New Energy Industry Development - Tianjin's new energy industry is expected to achieve an output value of 80 billion yuan in 2025, with a year-on-year growth of 9.3% [5] - The city aims to build a comprehensive new energy industry chain, focusing on wind, solar, lithium, and hydrogen sectors [5] - The number of enterprises in Tianjin's new energy industry chain exceeds 110, contributing significantly to the high-quality development of the manufacturing sector [5] Group 4: Policy and Institutional Support - The People's Bank of China Tianjin Branch has established a special working group with ten government departments to enhance cross-border RMB transaction efficiency [11] - The implementation of cross-border RMB facilitation policies has expanded from three regions to sixteen, significantly increasing the number of recognized quality enterprises [12] - The total amount of cross-border RMB facilitation business in Tianjin has exceeded 540 billion yuan [12]

齐鲁晚报.齐鲁壹点李可 1月17日，菏泽市医学会药物临床研究与评价专业委员会第一届成立大会暨临床试验质量管理规范培训班"在菏泽市立医院顺利召开，为当地医学领域带来 新的发展契机。 菏泽市立医院党委副书记、院长叶永强率先致辞，表达了对专业委员会成立的期望。随后由市医学会许玉朋副秘书长主持进行了选举会议，菏泽市立医院 孙国栋当选新主委并发表就职发言，山东省药学会药物临床研究与评价专委会主任李朝武、菏泽市医学会副会长巨昆、淮海经济区临床试验联盟会长刘大 跃也分别致辞。之后全体参会人员合影留念。 本次会议的成功举办，标志着菏泽市药物临床研究与评价工作迈向新台阶，期待专业委员会在推动医学发展、服务民众健康方面发挥更大作用。 学术交流会上，专家们带来精彩分享。安徽医科大学第一附属医院周焕教授解读了生物医学新技术临床研究新法规及临床试验工程创新与实践；山东大学 齐鲁医院李朝武教授对临床试验管理国际标准进行了解读。最后还安排了交流讨论环节。 药物临床研究与评价对推动医学创新、保障用药安全意义重大。菏泽市立医院作为当地重要医疗科研中心，一直致力于相关领域发展。此次分委会成立为 各方搭建了更高层次交流平台。 孙国栋主委表示，专委 ...

Core Points - The Yunnan Provincial Health Commission has announced the list of high-level health technology talent to be trained for 2025, including 30 "high-end medical talents," 60 "medical discipline leaders," and 90 "medical reserve talents" [1][2]. Group 1: Announcement Details - The announcement is based on the implementation plan issued by the Yunnan Provincial Health Commission and the Yunnan Provincial Finance Department [1]. - The selection process involved expert reviews and approvals from the provincial health commission's director's office and party committee meetings [1]. Group 2: Training Categories - The training categories include: - 30 individuals designated as "high-end medical talents" [1]. - 60 individuals designated as "medical discipline leaders" [1]. - 90 individuals designated as "medical reserve talents" [1]. Group 3: Public Feedback - The public can provide feedback on the announced list from January 13 to January 20, 2026 [2].

Group 1: Russia's Health Project and AI Development - Russia has launched a national health project called "New Technologies for Health Protection," with a budget of 37.5 billion rubles planned for 2025-2027, focusing on enhancing medical research efficiency and ensuring technological sovereignty [1] - The project supports clinical trials for 8 original drugs targeting cancer and cardiovascular diseases, the development of 12 original medical devices, and 8 technologies for treating neurodegenerative diseases [1] - Yandex, Russia's largest search engine, has developed a pediatric MRI analysis tool, marking it as one of the first AI medical products specifically for children, adhering to strict data security standards [1] Group 2: Advances in Neurodegenerative Disease Research - The Peter the Great St. Petersburg Polytechnic University has made progress in neurodegenerative disease research, completing preclinical trials of a compound named C20, which reduces amyloid plaque in Alzheimer's disease model mice without affecting survival or genomic stability [2] Group 3: AI and Digital Health in Germany - The German Cancer Research Center (DKFZ) has released an AI-based cancer imaging analysis tool that identifies early tumor characteristics with unprecedented speed and accuracy [11] - The Fraunhofer Society is developing new biosensors and AI algorithms for real-time monitoring of chronic disease patients, aiming to translate research into practical digital health products [11] - Munich University and other institutions are advancing the development of "digital twins" of the human body to simulate drug metabolism and disease progression, potentially accelerating virtual clinical trials [11] Group 4: Synthetic Biology Legislation in South Korea - South Korea's National Assembly has passed the "Synthetic Biology Promotion Act," establishing synthetic biology as a core national technology and aiming to enhance global competitiveness in this field [14] - The act mandates the Ministry of Science and ICT to develop a national plan every five years, creating a collaborative innovation system among government, research, and industry [14] - The government plans to invest 126.3 billion won in a national "biomanufacturing factory," which will automate the design, construction, and testing of biological components using AI technology [14] Group 5: Vaccine Development and Public Health in South Africa - Biovac has received regulatory approval to begin clinical trials for an oral cholera vaccine, marking the first locally produced vaccine in South Africa in over fifty years [16] - The University of Cape Town's South African Tuberculosis Vaccine Initiative has completed a Phase II clinical trial for a new tuberculosis vaccine candidate, achieving a 54% efficacy rate [16] - South African researchers have discovered broadly neutralizing antibodies effective against multiple HIV strains prevalent in Southern Africa, collaborating with the NIH to initiate Africa's first long-acting injectable antiretroviral drug trial for young women [16]